NAMS
NASDAQ · Biotechnology
Newamsterdam Pharma Co Nv
$31.01
+0.95 (+3.16%)
Financial Highlights (FY 2026)
Revenue
53.10M
Net Income
-281,545,298
Gross Margin
—
Profit Margin
-530.3%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 29.6% | 29.6% | 29.6% |
| Operating Margin | -386.9% | 7.8% | 8.2% | 7.5% |
| Profit Margin | -530.3% | 6.7% | 9.2% | 8.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 53.10M | 2.67B | 2.72B | 2.95B |
| Gross Profit | — | 789.14M | 806.06M | 871.89M |
| Operating Income | -205,450,695 | 208.37M | 222.76M | 221.95M |
| Net Income | -281,545,298 | 178.81M | 249.35M | 248.71M |
| Gross Margin | — | 29.6% | 29.6% | 29.6% |
| Operating Margin | -386.9% | 7.8% | 8.2% | 7.5% |
| Profit Margin | -530.3% | 6.7% | 9.2% | 8.4% |
| Rev Growth | — | +5.8% | +24.9% | +4.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 1.28B | 1.26B | 1.36B |
| Total Equity | — | 1.84B | 1.76B | 1.83B |
| D/E Ratio | — | 0.69 | 0.72 | 0.74 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -293,399,142 | 313.99M | 355.91M | 385.93M |
| Free Cash Flow | — | 105.97M | 147.67M | 144.03M |